MedTrace Logo

WEUSKOP5723: Prostate Cancer Study

NCT01767363 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2016-11-09

No results posted yet for this study

Summary

This retrospective cohort study will assess the association of benign prostatic hyperplasia (BPH) treatment (5-alpha reductase inhibitors (5ARI) and alpha-blocker medications) with the occurrence of prostate cancer related mortality. This study will also assess a number of secondary endpoints including prostate cancer mortality or metastatic prostate cancer, and all cause mortality.

Conditions

  • Prostatic Hyperplasia

Interventions

OTHER

5-alpha reductase inhibitors

Use of 5-alpha reductase inhibitors over the course of the study period.

OTHER

Alpha-blockers

Use of alpha-blockers over the study period.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-03-31
Completion
2016-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01767363 on ClinicalTrials.gov